Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVascular has secured $10.87 million in series C financing which, the company believes, will support the clinical development of BioVascular's therapeutics targeting platelet-mediated diseases, saratin and BVI-007.
Subscribe to our email newsletter
Funds raised through this financing will allow BioVascular to complete ongoing clinical trials of its two compounds, saratin and BVI-007. The company has raised a total of $18.87 million to date. In connection with the financing, Martin partner of BB Biotech will join BioVascular’s board of directors.
John Parrish, CEO of BioVascular, said: “With the support of Domain Associates and Merck KGaA, BioVascular has built a solid strategy for advancing our two clinical candidates.”